PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31141702-3 2019 Lenalidomide did not affect the viability or expression of costimulatory molecules, but it potently suppressed the production of the key inflammatory cytokines IL-12 and IL-23, and enhanced the production of the anti-inflammatory cytokine IL-10 by CD1c+ DCs. Lenalidomide 0-12 interleukin 10 Homo sapiens 239-244 29986852-10 2018 Change in CSF interleukin-10 at 1 month correlated with clinical response and response duration to lenalidomide. Lenalidomide 99-111 interleukin 10 Homo sapiens 14-28 34952465-10 2022 In vivo study showed that lenalidomide inhibited pro-inflammatory cytokines TNF-alpha and IL-6 while enhanced anti-fibrotic cytokines IFN-gamma and IL-10 in bleomycin-induced inflammation model, and attenuated pulmonary fibrosis and collagen deposition in the following fibrosis stage. Lenalidomide 26-38 interleukin 10 Homo sapiens 148-153 24482747-4 2013 In particular, lenalidomide has been shown to stimulate the cytotoxic functions of T lymphocytes and natural killer cells, to limit the immunosuppressive impact of regulatory T cells, and to modulate the secretion of a wide range of cytokines, including tumor necrosis factor alpha, interferon gamma as well as interleukin (IL)-6, IL-10, and IL-12. Lenalidomide 15-27 interleukin 10 Homo sapiens 331-336 22733396-4 2013 We demonstrate that exposure to lenalidomide in the context of T-cell expansion with direct ligation of CD3/CD28 complex results in polarization toward a Th1 phenotype characterized by increased IFN-gamma, but not IL-10 expression. Lenalidomide 32-44 interleukin 10 Homo sapiens 214-219 21748755-6 2012 RESULTS: Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13. Lenalidomide 24-36 interleukin 10 Homo sapiens 219-224 29379494-0 2017 The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Lenalidomide 121-133 interleukin 10 Homo sapiens 16-21 29379494-5 2017 Furthermore, experiments to assess the role of lenalidomide, an immunomodulatory agent with direct antitumor effect as well as pleiotropic activity on the immune system, showed that this agent prevents a CXCL12-induced increase in p-S727-STAT3 and the IL-10 response by CLL cells. Lenalidomide 47-59 interleukin 10 Homo sapiens 252-257 29379494-6 2017 Lenalidomide also suppressed IL-10-induced Y705-STAT3 phosphorylation in healthy T cells, thus reversing CLL-induced T-cell dysfunction. Lenalidomide 0-12 interleukin 10 Homo sapiens 29-34 29379494-8 2017 Lenalidomide appears to be able to reverse CLL-induced immunosuppression through including abrogation of the CXCL12-CXCR4-S727-STAT3-mediated IL-10 response by CLL cells and prevention of IL-10-induced phosphorylation of Y705-STAT3 in T cells. Lenalidomide 0-12 interleukin 10 Homo sapiens 142-147 29379494-8 2017 Lenalidomide appears to be able to reverse CLL-induced immunosuppression through including abrogation of the CXCL12-CXCR4-S727-STAT3-mediated IL-10 response by CLL cells and prevention of IL-10-induced phosphorylation of Y705-STAT3 in T cells. Lenalidomide 0-12 interleukin 10 Homo sapiens 188-193 25398834-8 2015 Gene expression signature, induced by lenalidomide in nurse-like cells, indicated a reduction of pivotal pro-survival signals for chronic lymphocytic leukemia, such as CCL2, IGF1, CXCL12, HGF1, and supported a modulation towards M1 phenotype with high IL2 and low IL10, IL8 and CD163. Lenalidomide 38-50 interleukin 10 Homo sapiens 264-268 32761232-4 2020 Both lenalidomide and pomalidomide dose-dependently inhibited interleukin-12 (IL-12) and TNF production and STAT4 expression, and enhanced IL-10 production in response to LPS. Lenalidomide 5-17 interleukin 10 Homo sapiens 139-144 32321757-5 2020 Pharmacological targeting of IKZF3 with the drug lenalidomide showed that IKZF3 is required for anti-CD3/CD28 mAb-mediated induction of IL-10 but is dispensable for ex vivo IL-10 expression. Lenalidomide 49-61 interleukin 10 Homo sapiens 136-141